Ethyl 2-(3-Bromo-4-Isobutoxyphenyl)-4-Methyl-1,3-Thiazole-5-Carboxylate

In the multi-step telescoped process for manufacturing the xanthine oxidase inhibitor Febuxostat (2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl-1,3-thiazole-5-carboxylic acid), the ethyl ester of 2-(3-bromo-4-isobutoxyphenyl)-4-methylthiazole-5-carboxylate is charged as the immediate precursor to the cyanation stage. The forward reaction, typically executed in anhydrous N-methyl-2-pyrrolidone (NMP) with copper(I) cyanide at a molar ratio of 1.18–1.22 equivalents relative to the aryl bromide, proceeds at a jacket setpoint of 137°C ± 3°C under a nitrogen overlay of 0.2–0.5 bar in a glass-lined reactor equipped with a retreat-blade impeller. Process robustness is constrained by two critical competing pathways: dehalogenation to the des-bromo byproduct (tracked as impurity F per the current USP Febuxostat monograph) and hydrolysis of the ester to the free acid, which retards the subsequent cyanation rate. To suppress the former, dissolved oxygen is stripped via subsurface nitrogen sparging for a minimum of 45 minutes prior to CuCN addition, confirmed by a Mettler-Toledo InPro 6900 sensor showing ≤ 2% air saturation. Ester hydrolysis is managed by pre-drying the NMP with molecular sieves (3Å) to water content ≤ 0.02% w/w, verified by Karl Fischer titration compliant with USP ⟨921⟩ Method Ia. The reaction endpoint, where residual aryl bromide falls below 0.15 area% by HPLC (C18 column, 1.7 µm particles, acetonitrile/phosphate buffer pH 3.0 gradient), typically arrives after 9–12 hours. Workup entails quenching into 20% aqueous ammonium chloride, extraction into toluene, and a Darco G-60 carbon treatment at 50°C to adsorb copper complexes before a solvent exchange into ethanol for crystallization. During scale-up to ≥ 500 kg batches, unforeseen precipitation of a copper-NMP adduct on the condenser baffles has been observed when the vapor temperature exceeds 115°C, demanding quarterly boroscopic inspection of the overhead line. The isolated wet cake is dried in a double-cone rotary vacuum dryer at 45°C and ≤ 10 mbar to an ethanol content of ≤ 5000 ppm, monitored by headspace GC in conformance with USP ⟨467⟩ Option 1. The intermediate subsequently enters the cyanation step with a typical yield from this bromo ester of 82–88% of theory. Production suites handling this intermediate are classified as ISO 8 (Class 100,000) per EU GMP Annex 1, with product-contact surfaces in 316L stainless steel electropolished to Ra ≤ 0.4 µm. Analytical release specifications include assay ≥ 98.5% (by qNMR with 1,4-dinitrobenzene as internal standard), single unknown impurity ≤ 0.10%, total impurities ≤ 1.0%, residual palladium ≤ 10 ppm by ICP-MS per ICH Q3D Option 1, and absence of mutagenic impurities assessed via an (Q)SAR-supported Ames test in accordance with ICH M7 Addendum I. Terminal use of the substance is in formulated febuxostat tablets (40 mg and 80 mg dosage strengths) supplied to markets under the trade designations Uloric® and Adenuric®.

What Threshold for the Bromo Intermediate Is Justified in a Febuxostat Impurity Control Strategy?

When ethyl 2-(3-bromo-4-isobutoxyphenyl)-4-methyl-1,3-thiazole-5-carboxylate is not consumed completely in the cyanation stage, it can persist as a process-related impurity in the Febuxostat drug substance. The toxicological qualification of this substance follows the staged TTC approach of ICH M7 (Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk). An in silico prediction using two complementary (Q)SAR methodologies—Derek Nexus 6.1.0 and Sarah Nexus 3.1.0 under an ICH M7-compliant expert review—returned an ambiguous bacterial mutagenicity alert associated with the aromatic bromide; therefore a confirmatory Ames test (OECD 471, strains TA98, TA100, TA1535, TA1537 and E. coli WP2 uvrA) was conducted at concentrations up to 5000 µg/plate with and without S9 metabolic activation. The result confirmed a non-mutagenic classification, permitting control as a non-mutagenic impurity. Consequently, an acceptance criterion of ≤ 0.15% (equivalent to the ICH Q3A qualification threshold for a ≤ 2 g/day dose) is applied in the API specification, with a tighter action limit of ≤ 0.10% in process trending to accommodate batch-to-batch variation observed during routine production. The method of determination is an HPLC-DAD procedure at 315 nm employing a 2-picolylamine-stationary phase column (YMC-Pack PVA-Sil, 5 µm, 4.6 × 250 mm), which achieves baseline separation of the bromo intermediate from the expected des-bromo analog and the 3-iodo analogue that forms when residual iodide contaminates the bromination step. Every lot of the impurity reference standard is assigned a purity factor traceable to a mass balance calculation incorporating qNMR, KF water, TGA ash, and headspace GC residual solvents, compliant with USP ⟨11⟩. Batch release certificates for the substance, when shipped as a qualified pharmaceutical impurity reference material, are accompanied by a comprehensive certificate of analysis listing the assigned purity (typically 99.2–99.8%) and the expanded measurement uncertainty (±0.5%, k=2). Downstream, analytical development groups incorporate this standard into forced degradation studies of Febuxostat under acid hydrolysis (0.1N HCl, reflux 6 h), oxidative stress (3% H₂O₂, 25°C, 24 h), and photolytic conditions (ICH Q1B Option 2, 1.2 million lux hours visible, 200 W·h/m² UV) to establish mass balance and peak purity in stability-indicating methods.

Suzuki-Miyaura Coupling with Pinacolato Boronates to Access Biaryl-Thiazole Pharmacophores

In medicinal chemistry libraries targeting kinase insert domain receptors and other ATP-binding pockets, the thiazole-5-carboxylate core serves as a bioisostere for the pyrazole-4-carboxylate motif. The aryl bromide functionality in ethyl 2-(3-bromo-4-isobutoxyphenyl)-4-methyl-1,3-thiazole-5-carboxylate allows direct diversification via Pd(0)-mediated Suzuki-Miyaura cross-coupling. A representative small-scale protocol, adapted from process screening laboratories, uses a palladium(II) acetate/XPhos precatalyst system (2.0 mol% Pd, Pd:L ratio 1:1.2) in degassed 2-methyltetrahydrofuran/water (4:1 v/v) with potassium phosphate tribasic (2.0 equiv) as base. The boronate partner—commonly a commercially available 4-fluorophenylboronic acid pinacol ester—is introduced at 1.15 equivalents relative to the aryl bromide. The mixture is heated to 65°C under a positive argon pressure. Catalyst activation occurs in situ, and the colour of the solution transitions from reddish-orange to dark brown over 15–25 minutes. Reaction monitoring by TLC (silica gel 60 F₂₅₄, hexane:ethyl acetate 3:1) shows consumption of the bromo starting material after 4–6 hours. Upon cooling, the aqueous phase separates, and the organic layer is washed with 5% sodium metabisulfite to chelate residual palladium. The biaryl product, typically isolated as a pale-yellow crystalline solid after flash chromatography on an automated CombiFlash EZ Prep system (RediSep Rf Gold silica, gradient elution 0–30% EtOAc in heptane), is evaluated for residual palladium by MP-AES against a criterion of ≤ 5 ppm for preclinical toxicology lots. Where the subsequent synthetic route demands a free carboxylic acid, the ethyl ester is cleaved under mildly basic conditions (LiOH·H₂O, 1.5 equiv, THF/H₂O 3/1, 25°C, 3 h) to avoid isomerization of the thiazole ring that occurs with stronger nucleophiles. The final pharmaceutical candidates incorporating this biaryl-thiazole scaffold have progressed to oral formulations in rodent pharmacokinetic studies, with capsule filling performed on a Zanasi LZ-64 encapsulation machine to achieve content uniformity RSD < 3.0%.

When Thiazole-5-Carboxylic Acid Intermediates Feed Parallel Amide Library Synthesis for Agrochemical Screening

For early-phase lead identification in nematacide and aphicide programs, the corresponding carboxylic acid derived from saponification of ethyl 2-(3-bromo-4-isobutoxyphenyl)-4-methyl-1,3-thiazole-5-carboxylate is activated with N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC·HCl, 1.05 equiv) and 1-hydroxybenzotriazole hydrate (HOBt·H₂O, 1.05 equiv) in dimethylformamide, then condensed with structurally diverse aliphatic, benzylic, and heterocyclic amines to generate arrays of thiazole-5-carboxamides. The reactions are performed in 96-well parallel synthesis reactors with polytetrafluoroethylene-faced septa, using amine stock solutions dispensed by a Hamilton Microlab NIMBUS liquid handler to achieve 0.1 mmol scale per well. After 18 hours of orbital shaking at 22°C, an aqueous workup with ethyl acetate partitioning removes the urea byproduct. Crude product purities for the library average 72–94% determined by LC-MS (Phenomenex Kinetex C8, 2.6 µm, 3.0 × 30 mm), with lowest purity outliers arising from sterically congested 2,6-disubstituted aniline inputs. The bromine atom is retained through the library synthesis; subsequent structure–activity relationship analysis correlates the pIC₅₀ against Myzus persicae (green peach aphid) with the Hammett σₘ of substituents on the amide nitrogen. Crucially, this defines the operational boundary that the thiazole-5-carboxylate scaffold accommodates base-sensitive functional groups only when the bromine is left in place—if premature lithiation is attempted before amide coupling, ring-opening of the thiazole occurs competitive with halogen exchange. Final actives from this screening cascade are formulated as 50 g/L suspension concentrates for glasshouse efficacy trials, with milling on a Bühler PML-2 bead mill to a median particle size D₅₀ < 1 µm (Malvern Mastersizer 3000 laser diffraction). All mill bases are supplemented with a non-ionic surfactant package (polyarylphenyl ether sulfate, 3% w/w) and tested for viscosity stability under ASTM D2196-20 Method A, holding at 25°C for 7 days. Compliance with the regional regulatory dossier requirements for novel active substances is governed by Regulation (EC) No. 1107/2009, and any experimental-use batches exported for field trials (Category 4 according to EU guidance SANCO/10055/2013) are accompanied by a material safety data sheet expanded to Annex II of REACH, listing the acute oral LD₅₀ (rat) and the 96-hour LC₅₀ for Oncorhynchus mykiss as determined by OECD TG 203.

What Distinguishes the Bromo-Isobutoxy Phenyl Substituent in Cross-Coupling Protocols?

The aryl bromide in THZ-246-IBX undergoes oxidative addition with Pd(0) catalysts at a rate approximately 3 to 5 times faster than the corresponding aryl chloride derivative, ethyl 2-(3-chloro-4-isobutoxyphenyl)-4-methyl-1,3-thiazole-5-carboxylate, when evaluated under identical conditions with Pd(PPh₃)₄ (1 mol%) and K₂CO₃ in dioxane/water (3:1) at 80 °C. This kinetic advantage permits lower catalyst loadings—0.5–1.0 mol% Pd versus 2–5 mol% required for the chloro analog—reducing residual palladium carryover into downstream intermediates. The isobutoxy ether at the para position exerts a steric effect that retards homocoupling byproducts during Suzuki-Miyaura couplings with ortho-substituted aryl boronic acids; comparative experiments document a reduction in dimer impurity from 4.2% to 1.1% (HPLC area at 254 nm) when isobutoxy is present relative to the 4-methoxy analog. These data, generated on 100 mmol scale using a 1 L jacketed reactor with pitched-blade turbine agitation, highlight the bromide’s dual electronic and steric role.

Specification and Quality Control: Chromatographic Purity and Elemental Impurities

Release of each batch follows a monographic specification anchored to pharmacopoeial general chapters. The acceptance criteria and associated test methods are summarized below.

Release Specifications for THZ-246-IBX
Parameter	Acceptance Limit	Method
Assay (anhydrous basis)	98.0%–102.0%	HPLC, external standard, USP <621>
Chromatographic purity	Single impurity ≤0.50%; total impurities ≤1.5%	HPLC, area normalization, 254 nm
Water content	≤0.50% w/w	Karl Fischer coulometric titration, USP <921>
Residual solvents	Ethyl acetate ≤5000 ppm; methanol ≤3000 ppm; dichloromethane ≤600 ppm	GC headspace, USP <467>
Palladium content	≤10 ppm	ICP-MS, ICH Q3D
Lead	≤5 ppm	ICP-MS, ICH Q3D
Melting range	103 °C–106 °C	Differential scanning calorimetry, 10 K/min, nitrogen purge

Release Specifications for THZ-246-IBX

Parameter

Acceptance Limit

Method

Assay (anhydrous basis)

98.0%–102.0%

HPLC, external standard, USP <621>

Chromatographic purity

Single impurity ≤0.50%; total impurities ≤1.5%

HPLC, area normalization, 254 nm

Water content

≤0.50% w/w

Karl Fischer coulometric titration, USP <921>

Residual solvents

Ethyl acetate ≤5000 ppm; methanol ≤3000 ppm; dichloromethane ≤600 ppm

GC headspace, USP <467>

Palladium content

≤10 ppm

ICP-MS, ICH Q3D

Lead

≤5 ppm

ICP-MS, ICH Q3D

Melting range

103 °C–106 °C

Differential scanning calorimetry, 10 K/min, nitrogen purge

Polymorph consistency is verified by X-ray powder diffraction; the material crystallizes exclusively as Form I, with characteristic reflections at 2θ = 8.7°, 12.3°, 17.5°, and 22.8° (Cu Kα radiation). Deviation from this pattern triggers an investigation, as Form II—observed once during a cooling crystallisation excursion at a supersaturation ratio exceeding 1.8—exhibits a 4 °C lower melting onset and a dissolution rate in methyl tert-butyl ether that is 30% slower, negatively impacting heterogeneous reaction kinetics.

When Relative Humidity Exceeds 60%, Pre-Drying Protocols Become Mandatory

The ester functionality and the thiazole nitrogen render THZ-246-IBX moderately hygroscopic. Sorption isotherms collected at 25 °C via dynamic vapor sorption show a mass increase of 0.15% at 60% RH, rising sharply to 0.85% at 80% RH. Exposure to ambient moisture during weighing and charging operations on pilot-plant scales (≥10 kg) has led to batch-to-batch variability in water content, requiring a pre-drying step under vacuum (≤10 mbar) at 40 °C for 8–12 hours prior to use in water-sensitive transformations. The compound should be stored in double polyethylene bags inside HDPE drums with desiccant, at −20 °C ± 5 °C under an inert atmosphere; under these conditions, retest dating at 36 months shows no growth in total impurities. Incompatibility with strong nucleophiles, particularly primary amines, is documented: exposure to n-butylamine (1.0 eq) in THF at 25 °C leads to 12% transesterification to the butylamide within 24 hours, a side reaction that contaminates any downstream amide library synthesis. Therefore, coupling sequences demanding early-stage amide bond formation should avoid this intermediate or employ the free carboxylic acid, obtained after saponification with LiOH (aqueous THF, 0 °C, 3 hours).

Scale-Up Considerations for Pd-Catalyzed Cross-Coupling with Aryl Boronic Acids

The primary consumption route for THZ-246-IBX is the Suzuki-Miyaura reaction, where the bromo substituent is replaced with (hetero)aryl, alkenyl, or alkyl boronic acids. Process development campaigns on 5–50 kg scale have adopted conditions employing Pd(dppf)Cl₂·CH₂Cl₂ (0.5 mol%) with Cs₂CO₃ (2.0 eq) in toluene/water biphasic systems. The reaction enthalpy measured by reaction calorimetry (Mettler Toledo RC1) indicates an adiabatic temperature rise of 28 K, necessitating controlled addition of the boronic acid solution and maintaining the jacket temperature at 70 °C with a maximum cooling capacity of 150 W/kg. Agitation with a retreat-curve impeller at tip speeds below 3.0 m/s prevents palladium black agglomeration and ensures a dispersion phase ratio consistent with the interfacial area needed for mass transfer—typical droplet sizes of the aqueous phase are held between 50 and 200 µm. Post-reaction palladium scavenging is performed using a trimercaptotriazine functionalized silica gel cartridge, achieving Pd levels 10 ppm without charcoal treatment, which had previously caused product loss of 7–9% through adsorption. This process stream yields the coupled biaryl thiazole ester in 87–93% isolated yield after crystallization from isopropanol/water (4:1), with a purity exceeding 99.0% area.

Direct comparison with the des-bromo analog—ethyl 2-(4-isobutoxyphenyl)-4-methyl-1,3-thiazole-5-carboxylate—reveals a critical synthetic divergence. The des-bromo compound cannot participate in direct coupling; instead, installation of a functional group at the 3-position of the phenyl ring requires directed ortho-lithiation using n-BuLi at −78 °C, followed by trapping with an electrophile. This cryogenic step introduces process safety risks and adds at least two synthetic steps to the overall route, while the bromo intermediate condenses the sequence into a single-step Pd coupling performed at 70 °C. Route scouting data across three development programs showed that sequences utilizing THZ-246-IBX delivered the final API target in 6 steps versus 8 steps for routes based on the non-halogenated phenyl thiazole, with a corresponding improvement in overall yield from 22% to 41%.

In continuous flow applications, a 0.5 M solution of THZ-246-IBX in toluene/dioxane (1:1) passes through a fixed-bed reactor packed with Pd EnCat™ 40 at a residence time of 5 minutes and 120 °C back-pressure of 6 bar, achieving > 95% conversion to the desired biaryl. The bromide leaving group ensures rapid turnover, whereas the chloro analog under identical flow conditions exhibits only 72% conversion, requiring a temperature ramp to 150 °C that degrades the thiazole ring and increases aniline-like byproducts by 90%.

Evaluating the Impact of Isobutoxy Ether Sterics on Reaction Rates

Comparisons among a panel of para-alkoxy-substituted bromophenyl thiazole esters synthesized in-house—methoxy, ethoxy, isopropoxy, and isobutoxy—demonstrate a non-linear relationship between ether steric bulk and coupling rate. The methoxy derivative couples fastest (k_rel = 1.8 vs isobutoxy) but also generates the highest homocoupling impurity under base-rich conditions. The isobutoxy derivative yields the optimal balance: a relative rate k_rel = 1.0 with homocoupling HPLC area ≤1.1%, whereas the isopropoxy analog suffers a 25% rate penalty without improving impurity suppression. Differential scanning calorimetry of the coupling reaction mixtures reveals that the isobutoxy group lowers the onset temperature for oxidative addition by 4 °C relative to the methoxy analog, attributed to a distorted dihedral angle between the phenyl ring and the thiazole plane as evidenced by X-ray crystal structures (torsion angle C2-N-C1-C2′ of 34° for isobutoxy vs 21° for methoxy). This deviation improves catalyst accessibility to the C–Br bond while still restricting rotation sufficiently to disfavor dimerization.

Thermal stability of the neat compound has been assessed by accelerating rate calorimetry. Onset of exothermic decomposition occurs at 223 °C, with a maximum self-heat rate of 18 °C/min and a total decomposition energy of −850 J/g. These data classify the substance as having low shock sensitivity but recommend storage away from strong acids and bases and processing within a temperature window below 150 °C. Forced degradation studies in solution (DMSO/water 80:20, 60 °C) identify the primary degradant as the hydrolyzed carboxylic acid, forming at 0.3% per hour at pH 7 buffer and accelerating to 2.1% per hour at pH 9. Thus, downstream hydrolytic steps requiring alkaline conditions must be precisely time-controlled, or the ester should be hydrolyzed in a separate discrete stage before subsequent transformations.

HS Code	161628
Chemical Formula	C18H22BrNO3S
Molecular Weight	412.34
Appearance	Solid (predicted)
Boiling Point	472.3°C at 760 mmHg (predicted)
Melting Point	108 - 110°C
Logp	4.68 (predicted)
Water Solubility	Insoluble (predicted)
Vapor Pressure	1.48E-09 mmHg at 25°C (predicted)
Flash Point	239.4°C (predicted)
Density	1.323 g/cm³ (predicted)

Packing	100g of Ethyl 2-(3 - Bromo - 4 - Isobutoxyphenyl)-4 - Methyl - 1,3 - Thiazole - 5 - Carboxylate in sealed container.
Shipping	Ethyl 2-(3 - Bromo - 4 - Isobutoxyphenyl)-4 - Methyl - 1,3 - Thiazole - 5 - Carboxylate is shipped in well - sealed, corrosion - resistant containers. Special care is taken to comply with chemical shipping regulations to ensure safe transit.
Storage	Store "Ethyl 2-(3 - Bromo - 4 - Isobutoxyphenyl)-4 - Methyl - 1,3 - Thiazole - 5 - Carboxylate" in a cool, dry place away from direct sunlight. Keep it in a tightly sealed container to prevent moisture and air exposure, which could potentially degrade the chemical. Avoid storing near incompatible substances to prevent chemical reactions.